Peptic ulcer disease is the presence of ulceration in the stomach and proximal duodenum commonly and in the lower esophagus, distal duodenum or jejunum infrequently. It is characterized by mucosal damage secondary to pepsin and gastric acid secretion.
It is the principal cause of upper gastrointestinal hemorrhage.
Appropriate therapy depends on the cause of peptic ulcer disease.
New drug applications approved by US FDA as of 1 - 15 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Vonoprazan is as effective as the proton pump inhibitor (PPI) lansoprazole for preventing peptic ulcer recurrence in patients receiving low-dose aspirin (LDA) therapy for cardiovascular or cerebrovascular protection, as shown in a phase III study. In addition, the drug appears to be well tolerated, with its preventive effect enduring with long-term use.
Helicobacter pylori (H. pylori) infection is associated with conditions such as gastritis, peptic ulcer, gastric cancer, and certain types of lymphoma. A common presenting complaint among all these H. pylori-related illnesses is dyspepsia. Dr Desmond Wai from the Desmond Wai Liver and Gastrointestinal Diseases Centre, Mount Elizabeth Novena Specialist Centre, Singapore, speaks on the important role general practitioners (GPs) play in recognizing, diagnosing, and treating H. pylori.
Rebamipide reduces atypical gastrointestinal (GI) symptoms, including gastroesophageal reflux, gastroparesis, peptic ulcer, and constipation, in patients with type 2 diabetes mellitus (T2DM), according to an investigator-initiated clinical trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Gastroenterology - Malaysia digital copy today!
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Men with advanced prostate cancer who have pre-existing cardiovascular disease (CVD) may have an elevated mortality risk after treatment with abiraterone acetate compared with men who do not have CVD, according to a study presented at AACR 2019.